As of July 1, 2023, LynxDx is no longer offering COVID-19 testing services.

The Difference in Informed Prostate Cancer Risk Screening

Offering physicians and patients a comprehensive, highly accurate risk assessment data set for prostate cancer care decisions.


MyProstateScore 2.0

Prostate cancer is the most common cancer among men in the U.S. and the second leading cause of cancer death. Yet, the traditional testing method, monitoring PSA, is just one piece in a complicated puzzle.

Knowing why a PSA is elevated, what the individual’s level of risk is, and if further testing is required create an important, full picture for predictive decision making.

MPS2 is a non-invasive urine test, offering a new level of simple, actionable, and data-driven decision making for providers and both biopsy naïve and prior negative patients.

You deserve the next generation in prostate cancer risk prediction for men’s health.

How It Works

Our Science. Clear Results. Your Decision.

A simple urine test that shines a highly sensitive light on a patient’s actual risk of prostate cancer when PSA is elevated. Our data models have combined those clinical factors most relevant for both biopsy naïve and prior negative patient populations. Our goal is to provide a solution with zero surprises for all involved.

Urine Sample icon

Simple Urine

It takes just 30 seconds, is non-invasive, and opens the door to peace of mind, with a 95%–-99% accurate prediction of risk for cancer.

Magnifying Glass icon

18 Biomarker
Array Analysis

MPS2 analyzes urine in an array of 18 genetic biomarkers including T2:ERG — the most specific prostate cancer biomarker available for identifying prostate cancer risk.

Report icon

Clear Patient
Risk Report

Determine your recommended best course of action based on an easy-to-read visual and technical illustration of patient risk factors.

Why LynxDx?

LynxDx provides best-in-class diagnostic testing services to help people live healthy and productive lives. We exist to support positive public health.


Early Prostate Cancer Risk Assessment

One in eight men will receive a prostate cancer diagnosis during their lifetime. The good news? Survival is nearly 100% when diagnosed early and contained within the prostate. When it spreads, however, the five-year survival is just 31%.

Early detection is critical for you and your family.

You can avoid subjective, invasive tests and receive a highly accurate prostate cancer screening to assess your current risk.

MyProstateScore 2.0 can give you and your urologist accurate data to make a personalized healthcare decision for you.

Stay Up-To-Date


Industry news, men’s health information, and expert prostate cancer and risk assessment research.